Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a ...

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

It may be difficult for Sana to protect its technology from the prying eyes of other Pharma and biotech companies, using patents and maintaining a veil of secrecy. For me personally, however ...

Since Sana released the data yesterday after market close, the biotech’s stock price has skyrocketed from $1.75 per share to $4.92 as of 10:30 a.m. ET today.

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according to ...